{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:43:19Z","timestamp":1792600999131,"version":"4.5.0"},"reference-count":27,"publisher":"Bulgarian Association for Promotion of Education and Science - BAPES","issue":"3","license":[{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["\u0420\u0435\u0434\u043a\u0438 \u0431\u043e\u043b\u0435\u0441\u0442\u0438 \u0438 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0430 \u0441\u0438\u0440\u0430\u0446\u0438"],"abstract":"<jats:p>\u041b\u0435\u0447\u0435\u043d\u0438\u0435\u0442\u043e \u043d\u0430 \u0445\u0435\u043f\u0430\u0440\u0438\u043d-\u0438\u043d\u0434\u0443\u0446\u0438\u0440\u0430\u043d\u0430\u0442\u0430 \u0442\u0440\u043e\u043c\u0431\u043e\u0446\u0438\u0442\u043e\u043f\u0435\u043d\u0438\u044f (\u0425\u0418\u0422) \u0435 \u043e\u0442 \u0440\u0435\u0448\u0430\u0432\u0430\u0449\u043e \u0437\u043d\u0430\u0447\u0435\u043d\u0438\u0435 \u0437\u0430 \u043d\u0430\u043c\u0430\u043b\u044f\u0432\u0430\u043d\u0435 \u043d\u0430 \u0440\u0438\u0441\u043a\u0430 \u043e\u0442 \u0442\u0440\u043e\u043c\u0431\u043e\u0435\u043c\u0431\u043e\u043b\u0438\u0447\u043d\u0438 \u0443\u0441\u043b\u043e\u0436\u043d\u0435\u043d\u0438\u044f \u0438 \u0441\u043c\u044a\u0440\u0442\u043d\u043e\u0441\u0442. \u041e\u0441\u043d\u043e\u0432\u0435\u043d \u043f\u0440\u0438\u043d\u0446\u0438\u043f \u043d\u0430 \u0442\u0435\u0440\u0430\u043f\u0438\u044f\u0442\u0430 \u0435 \u043d\u0435\u0437\u0430\u0431\u0430\u0432\u043d\u043e\u0442\u043e \u043f\u0440\u0435\u043a\u0440\u0430\u0442\u044f\u0432\u0430\u043d\u0435 \u043d\u0430 \u0445\u0435\u043f\u0430\u0440\u0438\u043d\u043e\u0432\u0430\u0442\u0430 \u0435\u043a\u0441\u043f\u043e\u0437\u0438\u0446\u0438\u044f, \u043f\u043e\u0441\u043b\u0435\u0434\u0432\u0430\u043d\u043e \u043e\u0442 \u0437\u0430\u043f\u043e\u0447\u0432\u0430\u043d\u0435 \u043d\u0430 \u0430\u043b\u0442\u0435\u0440\u043d\u0430\u0442\u0438\u0432\u0435\u043d \u043d\u0435\u0445\u0435\u043f\u0430\u0440\u0438\u043d\u043e\u0432 \u0430\u043d\u0442\u0438\u043a\u043e\u0430\u0433\u0443\u043b\u0430\u043d\u0442 \u0432 \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u043d\u0430 \u0434\u043e\u0437\u0430. \u0421\u0440\u0435\u0434 \u043d\u0430\u0439-\u0447\u0435\u0441\u0442\u043e \u0438\u0437\u043f\u043e\u043b\u0437\u0432\u0430\u043d\u0438\u0442\u0435 \u043d\u0435\u0445\u0435\u043f\u0430\u0440\u0438\u043d\u043e\u0432\u0438 \u0430\u043d\u0442\u0438\u043a\u043e\u0430\u0433\u0443\u043b\u0430\u043d\u0442\u0438 \u0441\u0430 \u0430\u0440\u0433\u0430\u0442\u0440\u043e\u0431\u0430\u043d, \u0431\u0438\u0432\u0430\u043b\u0438\u0440\u0443\u0434\u0438\u043d, \u0434\u0430\u043d\u0430\u043f\u0430\u0440\u043e\u0438\u0434, \u0444\u043e\u043d\u0434\u0430\u043f\u0430\u0440\u0438\u043d\u0443\u043a\u0441 \u0438 \u0434\u0438\u0440\u0435\u043a\u0442\u043d\u0438 \u043f\u0435\u0440\u043e\u0440\u0430\u043b\u043d\u0438 \u0430\u043d\u0442\u0438\u043a\u043e\u0430\u0433\u0443\u043b\u0430\u043d\u0442\u0438 (\u0414\u041e\u0410\u041a). \u0418\u0437\u0431\u043e\u0440\u044a\u0442 \u043d\u0430 \u043a\u043e\u043d\u043a\u0440\u0435\u0442\u043d\u043e \u0441\u0440\u0435\u0434\u0441\u0442\u0432\u043e \u0437\u0430\u0432\u0438\u0441\u0438 \u043e\u0442 \u0440\u0435\u0434\u0438\u0446\u0430 \u0444\u0430\u043a\u0442\u043e\u0440\u0438, \u0432\u043a\u043b\u044e\u0447\u0438\u0442\u0435\u043b\u043d\u043e \u0431\u044a\u0431\u0440\u0435\u0447\u043d\u0430 \u0438 \u0447\u0435\u0440\u043d\u043e\u0434\u0440\u043e\u0431\u043d\u0430 \u0444\u0443\u043d\u043a\u0446\u0438\u044f, \u0438\u043d\u0434\u0438\u0432\u0438\u0434\u0443\u0430\u043b\u0435\u043d \u0440\u0438\u0441\u043a \u043e\u0442 \u043a\u044a\u0440\u0432\u0435\u043d\u0435, \u043a\u043b\u0438\u043d\u0438\u0447\u043d\u0438\u044f \u043a\u043e\u043d\u0442\u0435\u043a\u0441\u0442 \u0438 \u043d\u0430\u043b\u0438\u0447\u043d\u043e\u0441\u0442\u0442\u0430 \u043d\u0430 \u0441\u044a\u043e\u0442\u0432\u0435\u0442\u043d\u0438\u0442\u0435 \u043c\u0435\u0434\u0438\u043a\u0430\u043c\u0435\u043d\u0442\u0438.\r\n\u041d\u0430\u0441\u0442\u043e\u044f\u0449\u0438\u044f\u0442 \u043e\u0431\u0437\u043e\u0440 \u043f\u0440\u0435\u0434\u0441\u0442\u0430\u0432\u044f \u0434\u0435\u0442\u0430\u0439\u043b\u0435\u043d \u0430\u043d\u0430\u043b\u0438\u0437 \u043d\u0430 \u0432\u0441\u044f\u043a\u0430 \u043e\u0442 \u0442\u0435\u0437\u0438 \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u043d\u0438 \u043e\u043f\u0446\u0438\u0438 \u0438 \u0441\u0438\u0441\u0442\u0435\u043c\u0430\u0442\u0438\u0437\u0438\u0440\u0430 \u0441\u044a\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u0438\u0442\u0435 \u043c\u0435\u0436\u0434\u0443\u043d\u0430\u0440\u043e\u0434\u043d\u0438 \u043f\u0440\u0435\u043f\u043e\u0440\u044a\u043a\u0438 \u0437\u0430 \u043b\u0435\u0447\u0435\u043d\u0438\u0435 \u043d\u0430 \u0425\u0418\u0422.<\/jats:p>","DOI":"10.36865\/2025.v16i3.225","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T13:53:45Z","timestamp":1760882025000},"page":"28-33","source":"Crossref","is-referenced-by-count":0,"title":["\u0422\u0435\u0440\u0430\u043f\u0438\u044f \u043d\u0430 \u0445\u0435\u043f\u0430\u0440\u0438\u043d-\u0438\u043d\u0434\u0443\u0446\u0438\u0440\u0430\u043d\u0430 \u0442\u0440\u043e\u043c\u0431\u043e\u0446\u0438\u0442\u043e\u043f\u0435\u043d\u0438\u044f","Treatment of heparin-induced thrombocytopenia"],"prefix":"10.36865","volume":"16","author":[{"given":"\u0410\u043d\u0434\u0440\u0438\u044f\u043d\u0430","family":"\u0411\u0430\u043d\u043a\u043e\u0432\u0430","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22878","published-online":{"date-parts":[[2025,10,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132-5.","DOI":"10.1160\/TH04-12-0825"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Nilius H, Sinitsa E, Studt JD, et al. Outcomes of Patients with Suspected Heparin-Induced Thrombocytopenia in a Contemporary Multicenter Cohort. Blood Adv. 2025.","DOI":"10.1182\/bloodadvances.2025016639"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-92.","DOI":"10.1182\/bloodadvances.2018024489"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96(3):846-51.","DOI":"10.1182\/blood.V96.3.846.015k09_846_851"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):340S-80S.","DOI":"10.1378\/chest.08-0677"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Aljabri A, Huckleberry Y, Karnes JH, et al. Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. Blood. 2016;128(26):3043-51.","DOI":"10.1182\/blood-2016-07-728030"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Marchetti M, Barelli S, Gleich T, et al. Managing argatroban in heparin-induced thrombocytopenia: A retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia. Br J Haematol. 2022;197(6):766-90.","DOI":"10.1111\/bjh.18120"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163(15):1849-56.","DOI":"10.1001\/archinte.163.15.1849"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest. 2006;129(6):1407-16.","DOI":"10.1378\/chest.129.6.1407"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Leo A, Winteroll S. Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants. Clin Diagn Lab Immunol. 2003;10(5):731-40.","DOI":"10.1128\/CDLI.10.5.731-740.2003"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Chong BH, Gallus AS, Cade JF, et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001;86(5):1170-5.","DOI":"10.1055\/s-0037-1616046"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Krauel K, Furll B, Warkentin TE, et al. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost. 2008;6(12):2160-7.","DOI":"10.1111\/j.1538-7836.2008.03171.x"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142(6):952-9.","DOI":"10.1067\/mhj.2001.119374"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Nilius H, Kaufmann J, Cuker A, et al. Comparative effectiveness and safety of anticoagulants for the treatment of heparin-induced thrombocytopenia. Am J Hematol. 2021;96(7):805-15.","DOI":"10.1002\/ajh.26194"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Goldfarb MJ, Blostein MD. Fondaparinux in acute heparin-induced thrombocytopenia: a case series. J Thromb Haemost. 2011;9(12):2501-3.","DOI":"10.1111\/j.1538-7836.2011.04489.x"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Warkentin TE, Pai M, Sheppard JI, et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9(12):2389-96.","DOI":"10.1111\/j.1538-7836.2011.04487.x"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Warkentin TE, Davidson BL, Buller HR, et al. Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest. 2011;140(2):366-73.","DOI":"10.1378\/chest.10-1599"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol. 2008;143(1):92-9.","DOI":"10.1111\/j.1365-2141.2008.07300.x"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Linkins LA, Warkentin TE, Pai M, et al. Design of the rivaroxaban for heparin-induced thrombocytopenia study. J Thromb Thrombolysis. 2014;38(4):485-92.","DOI":"10.1007\/s11239-014-1064-7"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012;119(10):2209-18.","DOI":"10.1182\/blood-2011-11-376293"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Welsby IJ, Krakow EF, Heit JA, et al. The association of anti-platelet factor 4\/heparin antibodies with early and delayed thromboembolism after cardiac surgery. J Thromb Haemost. 2017;15(1):57-65.","DOI":"10.1111\/jth.13533"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Pishko AM, Cuker A. Heparin-induced thrombocytopenia and cardiovascular surgery. Hematology Am Soc Hematol Educ Program. 2021;2021(1):536-44.","DOI":"10.1182\/hematology.2021000289"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Griffin BR, Bronsert M, Reece TB, et al. Thrombocytopenia After Cardiopulmonary Bypass Is Associated With Increased Morbidity and Mortality. Ann Thorac Surg. 2020;110(1):50-7.","DOI":"10.1016\/j.athoracsur.2019.10.039"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Vonderheide RH, Thadhani R, Kuter DJ. Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am J Med. 1998;105(1):27-32.","DOI":"10.1016\/S0002-9343(98)00128-4"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Muslem R, Caliskan K, Leebeek FWG. Acquired coagulopathy in patients with left ventricular assist devices. J Thromb Haemost. 2018;16(3):429-40.","DOI":"10.1111\/jth.13933"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Goel R, Ness PM, Takemoto CM, et al. Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality. Blood. 2015;125(9):1470-6.","DOI":"10.1182\/blood-2014-10-605493"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e495S-e530S.","DOI":"10.1378\/chest.11-2303"}],"container-title":["\u0420\u0435\u0434\u043a\u0438 \u0431\u043e\u043b\u0435\u0441\u0442\u0438 \u0438 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432\u0430 \u0441\u0438\u0440\u0430\u0446\u0438"],"original-title":[],"link":[{"URL":"https:\/\/journal.raredis.org\/index.php\/RBLS\/article\/download\/225\/223","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journal.raredis.org\/index.php\/RBLS\/article\/download\/225\/223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:04:16Z","timestamp":1792598656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.raredis.org\/index.php\/RBLS\/article\/view\/225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,19]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,10,19]]}},"URL":"https:\/\/doi.org\/10.36865\/2025.v16i3.225","relation":{},"ISSN":["1314-3581"],"issn-type":[{"value":"1314-3581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,19]]}}}